Yuhan Corporation Presents Phase 1b Results for Novel Anti-IgE Allergy Drug Lesigercept at EAACI 2026
Key Insights
Yuhan Corporation (search) presented Phase 1b clinical trial results for its novel anti-IgE allergy treatment Lesigercept (YH35324) at the EAACI 2026 annual symposium in Istanbul, Turkey.
Lesigercept is a long-acting, high-affinity IgETrap-Fc fusion protein designed to neutralize free IgE in the blood and regulate IgE-mediated allergic inflammatory responses.
The trial involving 46 subjects demonstrated a favorable safety profile with no dropouts due to adverse events, and blood free IgE decreased in a dose-dependent manner with long-lasting reduction effects.
Yuhan Corporation (search) announced on June 15 the presentation of Phase 1b clinical trial results for its investigational allergy treatment Lesigercept (development code: YH35324) at the European Association for Allergy and Clinical Immunology (EAACI) 2026 annual symposium held in Istanbul, Turkey. The announcement comes as the Korean pharmaceutical giant marks its centennial year, reinforcing its ambition to become a global innovative drugmaker.
Lesigercept is a novel drug candidate in the anti-immunoglobulin E (search) (anti-IgE) class, designed as a long-acting, high-affinity IgETrap-Fc fusion protein. The therapeutic is engineered to regulate IgE-mediated allergic inflammatory responses by neutralizing free IgE circulating in the blood, offering a potentially differentiated mechanism within the established anti-IgE treatment landscape.
Trial Design and Patient Population
The Phase 1b study enrolled a total of 46 subjects and was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic characteristics of repeated Lesigercept administration. The trial was structured across five cohorts: Cohorts 1 through 4 included healthy individuals and patients with allergic diseases (search) who had an atopic predisposition, while Cohort 5 enrolled patients with moderate or severe atopic dermatitis (search).
Safety and Pharmacodynamic Findings
According to the results presented at EAACI 2026, Lesigercept maintained a favorable safety profile even with repeated administration. Notably, no dropouts due to adverse events were reported, and no serious drug-related adverse events occurred during the study period.
Drug exposure was observed to increase with increasing dose. Critically, blood free IgE levels decreased in a dose-dependent manner, and the reduction effect demonstrated a tendency to be longer-lasting — a finding that supports the long-acting design of the IgETrap-Fc fusion protein construct.
Corporate Context
The clinical data presentation coincides with Yuhan Corporation (search)'s 100th anniversary. At a centennial ceremony held on June 20 at Willow House in Dongjak-gu, Seoul, CEO Cho Wook-je articulated the company's forward-looking vision: "Leaping into a global innovative pharmaceutical firm to go beyond Korean public health to contribute to the entire humanity, the journey of 'Great Yuhan, Global Yuhan' has begun once again."
Founded in 1926 by Korean independence activist and entrepreneur New Ilan, Yuhan Corporation (search) is the 11th listed company in Korea to reach the 100-year milestone. The company has stated its commitment to continuing the development of innovative medicines and expanding global partnerships, with Lesigercept representing one of its advancing pipeline assets in the immunology and allergy space.